A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine

NCT02959177 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

459

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: Galcanezumab
DRUG: Placebo

Sponsor

Eli Lilly and Company